- Home
- UAL vs BIIB Comparison
UAL vs BIIB Comparison
Compare UAL & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UAL | BIIB |
|---|---|---|
| Founded | 1934 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.6B | 24.2B |
| IPO Year | N/A | 1991 |
Fundamental Metrics
Financial Performance| Metric | UAL | BIIB |
|---|---|---|
| Price | $114.31 | $176.45 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 22 |
| Target Price | $129.50 | ★ $177.40 |
| AVG Volume (30 Days) | ★ 4.8M | 2.4M |
| Earning Date | 01-20-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.30 | N/A |
| EPS | 9.99 | ★ 10.97 |
| Revenue | ★ $58,369,000,000.00 | $10,065,900,000.00 |
| Revenue This Year | $4.52 | $3.58 |
| Revenue Next Year | $7.77 | N/A |
| P/E Ratio | ★ $11.42 | $16.14 |
| Revenue Growth | 4.24 | ★ 4.77 |
| 52 Week Low | $52.00 | $110.04 |
| 52 Week High | $116.32 | $185.17 |
Technical Indicators
Market Signals| Indicator | UAL | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 63.77 | 57.52 |
| Support Level | $112.65 | $168.56 |
| Resistance Level | $116.32 | $177.18 |
| Average True Range (ATR) | 2.90 | 4.78 |
| MACD | 0.40 | -0.81 |
| Stochastic Oscillator | 82.46 | 58.78 |
Price Performance
Historical ComparisonAbout UAL United Airlines Holdings Inc.
Chicago-based United Airlines is a major US network carrier with hubs in San Francisco, Chicago, Houston, Denver, Los Angeles, Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international and long-haul travel, especially across the Pacific, than its large US peers.
About BIIB Biogen Inc.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).